학술논문
A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445